Get the Stockscreener App
12.39
1.04%
-0.13
After Hours:
12.39
Greenwich Lifesciences Inc stock is traded at $12.39, with a volume of 70,482.
It is down -1.04% in the last 24 hours and down -3.58% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$12.52
Open:
$12.41
24h Volume:
70,482
Relative Volume:
2.44
Market Cap:
$162.86M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-17.70
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-8.29%
1M Performance:
-3.58%
6M Performance:
-19.02%
1Y Performance:
+16.67%
1-Day Range:
$12.15
$12.77
1-Week Range:
$12.15
$13.65
52-Week Range:
$8.00
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
12.39 | 162.86M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences reports shareholder meeting outcomes By Investing.com - Investing.com Australia
Maiden Holdings, Ltd. (NASDAQ:MHLD) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Invesco Dividend Achievers ETF (NASDAQ:PFM) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Boosts Holdings in LiveOne, Inc. (NASDAQ:LVO) - Defense World
Charles Schwab Investment Management Inc. Reduces Stock Position in iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) - Defense World
Quantum-Si incorporated (NASDAQ:QSI) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $335,000 Stock Position in Lifeway Foods, Inc. (NASDAQ:LWAY) - Defense World
Charles Schwab Investment Management Inc. Makes New Investment in Sunrise Realty Trust, Inc. (NASDAQ:SUNS) - Defense World
Charles Schwab Investment Management Inc. Grows Stake in Reservoir Media, Inc. (NASDAQ:RSVR) - Defense World
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Buys 6,968 Shares of Torrid Holdings Inc. (NYSE:CURV) - Defense World
Charles Schwab Investment Management Inc. Decreases Stock Holdings in FREYR Battery, Inc. (NYSE:FREY) - Defense World
Charles Schwab Investment Management Inc. Has $386,000 Stake in Priority Technology Holdings, Inc. (NASDAQ:PRTH) - Defense World
Vanguard International Dividend Appreciation ETF (NASDAQ:VIGI) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Contango Ore, Inc. (NYSEAMERICAN:CTGO) - Defense World
Charles Schwab Investment Management Inc. Sells 289,312 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Charles Schwab Investment Management Inc. Sells 10,340 Shares of Rentokil Initial plc (NYSE:RTO) - Defense World
Strawberry Fields REIT, Inc. (NYSEAMERICAN:STRW) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Acquires 2,806 Shares of Pioneer Bancorp, Inc. (NASDAQ:PBFS) - Defense World
Charles Schwab Investment Management Inc. Decreases Position in iLearningEngines, Inc. (NASDAQ:AILE) - Defense World
Charles Schwab Investment Management Inc. Has $230,000 Holdings in HireQuest, Inc. (NASDAQ:HQI) - Defense World
Charles Schwab Investment Management Inc. Trims Position in USCB Financial Holdings, Inc. (NASDAQ:USCB) - Defense World
Charles Schwab Investment Management Inc. Boosts Stock Position in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
Charles Schwab Investment Management Inc. Cuts Stock Position in Southland Holdings, Inc. (NASDAQ:SLND) - Defense World
Charles Schwab Investment Management Inc. Decreases Position in MediWound Ltd. (NASDAQ:MDWD) - Defense World
Charles Schwab Investment Management Inc. Has $204,000 Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
(GLSI) Trading Signals - Stock Traders Daily
Checkpoint stock on watch after FDA nod (CKPT:NASDAQ) - Seeking Alpha
(GLSI) Proactive Strategies - Stock Traders Daily
Greenwich LifeSciences Partners with GIM in Italy - The Manila Times
LVT Launches ACCESS Taskforce in Detroit in Collaboration with Retailers, State and Local Officials - The Manila Times
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Purchases 1,000 Shares - MarketBeat
Greenwich Lifesciences VP buys $12,910 in common stock - Investing.com
Trend Tracker for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Provides Update on Corporate Events - GlobeNewswire
SINTX Technologies Announces Stock Repurchase Program - The Manila Times
Greenwich LifeSciences Expands Presence at Major Cancer & Healthcare Conferences | GLSI Stock News - StockTitan
Stocks Retreat As Bond Yields Climb On A Hawkish Fed - Barchart
Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields - The Globe and Mail
Scoop Up Big Gains With 4 Stocks Witnessing Rise In Cash Flow - Barchart
Here Is What Could Be Next For Super Micro Computer As Deadline Gets Closer - Barchart
Stocks Tumble As Hawkish Fed And Strong US Economic News Boosts Bond Yields - Barchart
Stocks Retreat as Bond Yields Climb on a Hawkish Fed - The Globe and Mail
Applied Materials (AMAT-Q) QuotePress Release - The Globe and Mail
Greenwich LifeSciences Inc (GLSI) Quarterly 10-Q Report - Quartzy
Stocks Slip Ahead Of A Speech From Fed Chair Powell - Barchart
Stocks Close Lower On Hawkish Powell - Barchart
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bell-Boeing Secures Contract To Aid CMV-22 Osprey Aircraft Program - Barchart
Best Momentum Stocks To Buy For November 14th - Barchart
Food Prices Worried Most Voters, But Trump's Plans Likely Won't Lower Their Grocery Bills - Barchart
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Sep 26 '24 |
Buy |
14.63 |
1,500 |
21,945 |
5,536,102 |
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 12 '24 |
Buy |
13.85 |
800 |
11,080 |
263,148 |
| Patel Snehal | CEO and CFO |
Aug 06 '24 |
Buy |
13.81 |
2,000 |
27,620 |
5,534,602 |
| Patel Snehal | CEO and CFO |
Aug 05 '24 |
Buy |
13.18 |
5,500 |
72,490 |
5,532,602 |
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 02 '24 |
Buy |
15.15 |
1,000 |
15,150 |
262,348 |
| Patel Snehal | CEO and CFO |
Jul 23 '24 |
Buy |
15.89 |
1,500 |
23,835 |
5,527,102 |
| Thompson Jaye | VP Clinical Reg Affairs |
Jul 18 '24 |
Buy |
16.00 |
1,000 |
16,000 |
261,348 |
| Patel Snehal | CEO and CFO |
Jun 13 '24 |
Buy |
14.30 |
174,825 |
2,499,998 |
5,525,602 |
| Patel Snehal | CEO and CFO |
Apr 01 '24 |
Buy |
19.08 |
3,000 |
57,240 |
5,350,777 |
| Patel Snehal | CEO and CFO |
Mar 22 '24 |
Buy |
19.98 |
2,500 |
49,950 |
5,347,777 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):